MiNK Therapeutics, Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. MiNK is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic iNKT cell therapies. It reported no revenue; operations are funded through available cash and potential financing or collaboration sources.
Financial results and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | None reported | None reported | None reported | None reported |
| Research and development expense | $4.56 million | $5.88 million | $8.75 million | $11.15 million |
| General and administrative expense | $1.78 million | $1.82 million | $3.45 million | $3.92 million |
| Operating loss | $6.34 million | $7.70 million | $12.20 million | $15.07 million |
| Net loss | $6.20 million | $6.11 million | $11.88 million | $13.89 million |
| Net loss per share | $0.18 | $0.18 | $0.35 | $0.41 |
Gross margin and operating margin are not meaningful because the filing reports no revenue. Cash and cash equivalents were $10.62 million at June 30, 2023, down from $19.64 million at December 31, 2022. Six-month operating cash use was $8.52 million; cash declined by $9.01 million overall. Current assets were $11.05 million and current liabilities $11.46 million, implying a current ratio below 1. Total liabilities included $10.06 million due to related parties; the filing does not report conventional borrowings as debt. Accumulated deficit was $122.82 million and stockholders’ deficit was $9.50 million.
Changes versus comparable periods
- Q2 R&D expense declined 22% year over year, which management attributed mainly to clinical-trial timing and lower allocated Agenus service costs, partly offset by higher personnel costs. Six-month R&D expense also declined 22%.
- Six-month G&A expense declined 12%, primarily due to lower professional fees and allocated Agenus service costs, partly offset by higher personnel and stock-compensation costs.
- Q2 net loss increased from $6.11 million to $6.20 million despite lower operating expenses. The prior-year quarter included $1.56 million of other income related to the Walloon Region liability; no such other income was recorded in Q2 2023. Six-month net loss improved, also reflecting the prior-year period’s liability-forgiveness gain.
- Cash used in operations was modestly lower than in the first half of 2022 ($8.52 million versus $8.82 million), while cash on hand fell substantially from year-end.
Programs, outlook, and risks
- MiNK’s lead candidate, agenT-797, is in Phase 1 studies in solid tumors and viral ARDS. Management cited encouraging early clinical observations, including a gastric-cancer partial response ongoing at 10 months and reported survival benefit in viral ARDS. These are early, company-reported results and are not evidence of established efficacy.
- The company plans a randomized Phase 1/2 expansion study of agenT-797 in relapsed/refractory gastric cancer and is pursuing strategic collaboration and non-dilutive financing for viral ARDS. Discussions were underway; no definitive agreements were disclosed.
- MiNK-215 and MiNK-413 are engineered iNKT programs in preclinical development. IND-enabling work was underway, with an IND application targeted for 2024.
- Management believes June 30 cash will fund operations for more than one year from issuance of the statements, while warning that losses and negative cash flows are expected for the foreseeable future. Funding options include partnerships, licensing, debt, or equity. Agenus indicated willingness to provide certain loans if other funding is unavailable.
- A $2.3 million current liability relates to an advance from Belgium’s Walloon Region, which obtained a default judgment seeking repayment after alleging MiNK failed to provide required notice of discontinued regional research. The filing describes the matter but does not provide a clear resolution or final payment outcome.
- MiNK depends on Agenus for services and has a $10.1 million related-party balance that Agenus agreed not to require repayment of before September 30, 2024. Related-party services, shared operations, and allocated costs are significant considerations.
- The company says there were no material changes to the risk factors in its 2022 Form 10-K and no material legal proceedings. Management reported disclosure controls were effective and no material change in internal control over financial reporting.
Investor verification points
- Confirm the cash runway assumptions, expected clinical and manufacturing spend, and timing and terms of any financing or Agenus support.
- Review subsequent clinical-trial data, enrollment and study plans for agenT-797, and whether the stated 2024 IND target for MiNK-215 and MiNK-413 remains achievable.
- Check the status, enforceability, and potential cash impact of the Walloon Region judgment and related liability.
- Assess related-party balances and arrangements with Agenus, including repayment timing and the company’s reliance on shared services.
- Monitor cash burn, share issuance and dilution, given the continuing losses and absence of revenue.